Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 09-Aug-24 5:24 PM View:  | Rottinghaus Scott T. Chief Medical Officer | Enanta Pharmaceuticals Inc (ENTA) | 08-Aug-24 | Payment of Exercise | 1,466 | $12.73 | $18,662.20 | (7%) 20.25K to 18.78K | |
| 15-Jul-24 5:29 PM View: | Rottinghaus Scott T. Chief Medical Officer | Enanta Pharmaceuticals Inc (ENTA) | 15-Jul-24 | Option Exercise | 5,375 | $8.99 | $48,321.20 | 25% 21.72K to 27.09K | |
| 15-Jul-24 5:29 PM View: | Rottinghaus Scott T. Chief Medical Officer | Enanta Pharmaceuticals Inc (ENTA) | 15-Jul-24 | Planned Option Sale | 3,104 | $17.08 | $53,016.30 | (11%) 27.09K to 23.99K | |
| 15-Jul-24 5:29 PM View: | Rottinghaus Scott T. Chief Medical Officer | Enanta Pharmaceuticals Inc (ENTA) | 15-Jul-24 | Sale (Planned) | 2,271 | $17.08 | $38,788.70 | (9%) 23.99K to 21.72K | |
| 15-Jul-24 5:29 PM View: | Rottinghaus Scott T. Chief Medical Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Jul-24 | Planned Option Sale | 2,271 | $15.04 | $34,155.80 | (9%) 23.99K to 21.72K | |
| 15-Jul-24 5:29 PM View: | Rottinghaus Scott T. Chief Medical Officer | Enanta Pharmaceuticals Inc (ENTA) | 11-Jul-24 | Sale (Planned) | 4,299 | $15.07 | $64,785.90 | (15%) 28.29K to 23.99K | |
| 17-Jun-24 8:38 PM View: | Kieffer Tara Lynn Chief Product Strategy Officer | Enanta Pharmaceuticals Inc (ENTA) | 17-Jun-24 | Sale (Planned) | 7,266 | $12.33 | $89,589.80 | (18%) 39.61K to 32.34K | |
| 27-Feb-24 6:31 PM View: | Gardiner Nathaniel S. Chief Legal Officer | Enanta Pharmaceuticals Inc (ENTA) | 26-Feb-24 | Option Exercise | 5,187 | $8.99 | $46,631.10 | 5% 106.43K to 111.61K | |
| 14-Feb-24 8:09 PM View: | Mellett Paul J Chief Fin. & Admin Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Grant | 3,320 | -- | -- | 4% 93.55K to 96.87K | |
| 14-Feb-24 8:12 PM View: | Or Yat Sun Chief Scientific Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Payment of Exercise | 1,080 | $12.41 | $13,402.80 | (< 1%) 374.38K to 373.3K | |
| 14-Feb-24 8:18 PM View: | Gardiner Nathaniel S. Chief Legal Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Grant | 3,320 | -- | -- | 3% 104.08K to 107.4K | |
| 14-Feb-24 8:21 PM View: | Kieffer Tara Lynn Chief Product Strategy Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Grant | 3,320 | -- | -- | 9% 37.26K to 40.58K | |
| 14-Feb-24 8:23 PM View: | Luu Brendan Chief Business Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Grant | 3,320 | -- | -- | 9% 36.74K to 40.06K | |
| 14-Feb-24 8:00 PM View: | Luly Jay R. President and CEO Director | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Grant | 5,400 | -- | -- | < 1% 806.79K to 812.19K | |
| 14-Feb-24 8:09 PM View: | Mellett Paul J Chief Fin. & Admin Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Payment of Exercise | 973 | $12.41 | $12,074.90 | (1%) 96.87K to 95.9K | |
| 14-Feb-24 8:15 PM View: | Rottinghaus Scott T. Chief Medical Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Grant | 2,576 | -- | -- | 10% 26.47K to 29.04K | |
| 14-Feb-24 8:18 PM View: | Gardiner Nathaniel S. Chief Legal Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Payment of Exercise | 973 | $12.41 | $12,074.90 | (< 1%) 107.4K to 106.43K | |
| 14-Feb-24 8:21 PM View: | Kieffer Tara Lynn Chief Product Strategy Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Payment of Exercise | 973 | $12.41 | $12,074.90 | (2%) 40.58K to 39.61K | |
| 14-Feb-24 8:23 PM View: | Luu Brendan Chief Business Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Payment of Exercise | 973 | $12.41 | $12,074.90 | (2%) 40.06K to 39.08K | |
| 14-Feb-24 8:12 PM View: | Or Yat Sun Chief Scientific Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Grant | 3,680 | -- | -- | < 1% 370.69K to 374.38K | |
| 14-Feb-24 8:15 PM View: | Rottinghaus Scott T. Chief Medical Officer | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Payment of Exercise | 755 | $12.41 | $9,369.55 | (3%) 29.04K to 28.29K | |
| 14-Feb-24 8:00 PM View: | Luly Jay R. President and CEO Director | Enanta Pharmaceuticals Inc (ENTA) | 12-Feb-24 | Payment of Exercise | 1,584 | $12.41 | $19,657.40 | (< 1%) 812.19K to 810.61K | |
| 15-Dec-23 8:08 PM View: | Vance Terry Director | Enanta Pharmaceuticals Inc (ENTA) | 13-Dec-23 | Sale | 15,295 | $9.12 | $139,490.00 | (73%) 21.09K to 5.8K | |
| 06-Dec-23 8:31 PM View: | Luu Brendan Sr. VP, Business Dev. | Enanta Pharmaceuticals Inc (ENTA) | 05-Dec-23 | Sale | 2,125 | $9.63 | $20,463.80 | (5%) 38.86K to 36.74K | |
| 06-Dec-23 8:17 PM View: | Luly Jay R. President and CEO Director | Enanta Pharmaceuticals Inc (ENTA) | 05-Dec-23 | Sale | 7,230 | $9.63 | $69,624.90 | (< 1%) 814.02K to 806.79K | |
| 06-Dec-23 8:19 PM View: | Mellett Paul J Sr. VP, Finance & Admin. & CFO | Enanta Pharmaceuticals Inc (ENTA) | 05-Dec-23 | Sale | 2,412 | $9.63 | $23,227.60 | (3%) 95.96K to 93.55K | |
| 06-Dec-23 8:24 PM View: | Rottinghaus Scott T. Sr. VP & CMO | Enanta Pharmaceuticals Inc (ENTA) | 05-Dec-23 | Sale | 534 | $9.63 | $5,142.42 | (2%) 27.0K to 26.47K | |
| 06-Dec-23 8:22 PM View: | Or Yat Sun Sr. VP, R&D & CSO | Enanta Pharmaceuticals Inc (ENTA) | 05-Dec-23 | Sale | 2,412 | $9.63 | $23,227.60 | (< 1%) 373.11K to 370.69K | |
| 06-Dec-23 8:26 PM View: | Gardiner Nathaniel S. Sr. VP & General Counsel | Enanta Pharmaceuticals Inc (ENTA) | 05-Dec-23 | Sale | 2,412 | $9.63 | $23,227.60 | (2%) 106.49K to 104.08K | |
| 06-Dec-23 8:29 PM View: | Kieffer Tara Lynn Sr. VP, New Prod. Strat. & Dev | Enanta Pharmaceuticals Inc (ENTA) | 05-Dec-23 | Sale | 2,125 | $9.63 | $20,463.80 | (5%) 39.38K to 37.26K | |
| 05-Dec-23 9:15 PM View: | Or Yat Sun Sr. VP, R&D & CSO | Enanta Pharmaceuticals Inc (ENTA) | 01-Dec-23 | Payment of Exercise | 1,595 | $9.49 | $15,136.50 | (< 1%) 374.7K to 373.11K | |
| 05-Dec-23 9:19 PM View: | Gardiner Nathaniel S. Sr. VP & General Counsel | Enanta Pharmaceuticals Inc (ENTA) | 01-Dec-23 | Payment of Exercise | 1,595 | $9.49 | $15,136.50 | (1%) 108.09K to 106.49K | |
| 05-Dec-23 9:08 PM View: | Luly Jay R. President and CEO Director | Enanta Pharmaceuticals Inc (ENTA) | 01-Dec-23 | Payment of Exercise | 5,787 | $9.49 | $54,918.60 | (< 1%) 819.81K to 814.02K | |
| 05-Dec-23 9:21 PM View: | Kieffer Tara Lynn Sr. VP, New Prod. Strat. & Dev | Enanta Pharmaceuticals Inc (ENTA) | 01-Dec-23 | Payment of Exercise | 753 | $9.49 | $7,145.97 | (2%) 40.14K to 39.38K | |
| 05-Dec-23 9:24 PM View: | Luu Brendan Sr. VP, Business Dev. | Enanta Pharmaceuticals Inc (ENTA) | 01-Dec-23 | Payment of Exercise | 753 | $9.49 | $7,145.97 | (2%) 39.61K to 38.86K | |
| 05-Dec-23 9:11 PM View: | Mellett Paul J Sr. VP, Finance & Admin. & CFO | Enanta Pharmaceuticals Inc (ENTA) | 01-Dec-23 | Payment of Exercise | 1,595 | $9.49 | $15,136.50 | (2%) 97.56K to 95.96K | |
| 09-Aug-24 5:24 PM View: | Rottinghaus Scott T. Chief Medical Officer | Enanta Pharmaceuticals Inc (ENTA) | 08-Aug-23 | Payment of Exercise | 1,467 | $17.23 | $25,276.40 | (5%) 27.0K to 25.53K | |
| 19-Apr-23 7:25 PM View: | Gardiner Nathaniel S. Sr. VP & General Counsel | Enanta Pharmaceuticals Inc (ENTA) | 18-Apr-23 | Option Exercise | 6,667 | $30.00 | $200,010.00 | 7% 101.42K to 108.09K | |
| 17-Mar-23 6:46 PM View: | Vance Terry Director | Enanta Pharmaceuticals Inc (ENTA) | 16-Mar-23 | Option Exercise | 5,800 | $14.00 | $81,200.00 | 38% 15.29K to 21.09K | |
| 17-Mar-23 6:37 PM View: | Or Yat Sun Sr. VP & CSO | Enanta Pharmaceuticals Inc (ENTA) | 15-Mar-23 | Option Exercise | 13,925 | $14.00 | $194,950.00 | 4% 374.7K to 388.63K | |
| 17-Mar-23 6:37 PM View: | Or Yat Sun Sr. VP & CSO | Enanta Pharmaceuticals Inc (ENTA) | 15-Mar-23 | Planned Option Sale | 13,925 | $44.45 | $618,960.00 | (4%) 388.63K to 374.7K | |
| 17-Mar-23 6:41 PM View: | Mellett Paul J Treasurer and CFO | Enanta Pharmaceuticals Inc (ENTA) | 15-Mar-23 | Planned Option Sale | 10,440 | $44.43 | $463,802.00 | (10%) 108.0K to 97.56K | |
| 17-Mar-23 6:41 PM View: | Mellett Paul J Treasurer and CFO | Enanta Pharmaceuticals Inc (ENTA) | 15-Mar-23 | Option Exercise | 10,440 | $14.00 | $146,160.00 | 11% 97.56K to 108.0K | |
| 14-Mar-23 6:26 PM View: | Luly Jay R. President and CEO Director | Enanta Pharmaceuticals Inc (ENTA) | 13-Mar-23 | Option Exercise | 27,912 | $14.00 | $390,768.00 | 3% 819.81K to 847.72K | |
| 14-Mar-23 6:26 PM View: | Luly Jay R. President and CEO Director | Enanta Pharmaceuticals Inc (ENTA) | 13-Mar-23 | Planned Option Sale | 27,912 | $45.16 | $1,260,630.00 | (3%) 847.72K to 819.81K | |
| 15-Feb-23 8:56 PM View: | Luly Jay R. President and CEO Director | Enanta Pharmaceuticals Inc (ENTA) | 13-Feb-23 | Payment of Exercise | 20,591 | $52.77 | $1,086,590.00 | (3%) 819.81K to 799.22K | |
| 15-Feb-23 9:44 PM View: | Mellett Paul J Treasurer and CFO | Enanta Pharmaceuticals Inc (ENTA) | 13-Feb-23 | Grant | 20,997 | -- | -- | 25% 83.46K to 104.46K | |
| 15-Feb-23 9:46 PM View: | Or Yat Sun Sr. VP & CSO | Enanta Pharmaceuticals Inc (ENTA) | 13-Feb-23 | Grant | 23,267 | -- | -- | 6% 359.19K to 382.45K | |
| 15-Feb-23 9:51 PM View: | Kieffer Tara Lynn Sr. VP, New Product Dev. | Enanta Pharmaceuticals Inc (ENTA) | 13-Feb-23 | Grant | 20,997 | -- | -- | 81% 25.87K to 46.86K | |
| 15-Feb-23 9:54 PM View: | Luu Brendan Sr. VP, Business Dev. | Enanta Pharmaceuticals Inc (ENTA) | 13-Feb-23 | Payment of Exercise | 6,416 | $52.77 | $338,572.00 | (14%) 46.03K to 39.61K |
